Publication

Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

Authors not recorded

Clin Cancer Res2001PMID 11595686stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (9)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 9

cancerMalignant Ovarian Neoplasmcivic_curation1.00
drugCarboplatincivic_curation1.00
drugCisplatincivic_curation1.00
geneTP53civic_curation1.00
variantTP53 ALTERATIONcivic_curation1.00
variantTP53 CONSERVED DOMAIN MUTcivic_curation1.00
variantTP53 Overexpressioncivic_curation1.00
variantTP53 R273Lcivic_curation1.00
variantTP53 Y234Ccivic_curation1.00

Curated evidence

Evidence citing this paper (7)

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TP53 ALTERATION2
(prognostic)	Malignant Ovarian Neoplasm	Prognostic	B	Supports Poor Outcome	4	accepted	EID3014 In a study of invasive ovarian carcinoma patients who had undergone surgery, the p53 alteration variant was defined as p53 mutation or p53 overexpression by immunostain (>10% positive). Patients with … (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic
Carboplatin + CisplatinSubstitutes	Malignant Ovarian Neoplasm	Predictive	B	Supports Resistance	4	accepted	EID2771 In a group of patients with invasive ovarian carcinoma who had undergone surgery, a subset of 74 patients treated with platinum based chemotherapy were assessed for p53 alteration (p53 mutation or p5… (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic
TP53 CONSERVED DOMAIN MUT1
(prognostic)	Malignant Ovarian Neoplasm	Prognostic	B	Supports Poor Outcome	3	accepted	EID2993 Patients with conserved domain p53 mutation (n=61) were compared with those with wild type or non-conserved domain p53 mutation (n=117) in a cohort of 178 invasive ovarian carcinoma patients who had u… (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic
TP53 Overexpression2
(prognostic)	Malignant Ovarian Neoplasm	Prognostic	B	Supports Poor Outcome	3	accepted	EID2697 p53 overexpression (>10% positive stained nuclei) was found in 110 cases from a 178 patient cohort with invasive ovarian carcinoma who had undergone surgery. Overexpression of p53 was correlated with … (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic
Carboplatin + CisplatinSubstitutes	Malignant Ovarian Neoplasm	Predictive	B	Supports Resistance	3	accepted	EID3013 In a study involving patients with invasive ovarian carcinoma who had undergone surgery, a subset of 73 patients were classified via response to platinum-based chemotherapy as sensitive or resistant/r… (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic
TP53 R273L1
Carboplatin + CisplatinSubstitutes	Malignant Ovarian Neoplasm	Predictive	C	Supports Resistance	—	accepted	EID2286 Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A … (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic
TP53 Y234C1
Carboplatin + CisplatinSubstitutes	Malignant Ovarian Neoplasm	Predictive	C	Supports Resistance	—	accepted	EID2745 Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A … (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic